Modern Vascular Announces Hiring of Dr. Steve Berkowitz

Modern Vascular, a pioneering medical group dedicated to preventing amputation through the treatment of peripheral artery disease (PAD), today announced the hiring of Dr. Steve Berkowitz, a nationally recognized healthcare leader with over 25 years of experience in senior management, protocol standardization, and clinical oversight.

Previous Experience

Dr. Berkowitz comes to Modern Vascular from Banner Health in Phoenix, Arizona, where he served as the organization’s Medical Director of Specialty Performance Improvement. Prior to that position, he was the Chief Physician Executive and medical group president for Northern Light Health, a nine-hospital system in Maine. He’s also held the title of Chief Medical Officer at St. David’s Healthcare, a six-hospital system in Austin, Texas and at the Central and West Texas Division of HCA, which was awarded the Texas Award for Performance Excellence and the prestigious Malcolm Baldrige National Quality award.

“I am thrilled to join the Modern Vascular team,” Dr. Berkowitz said. “The organization is dedicated to saving patients from the unnecessary risk and cost associated with amputations. I have seen the work that is being done in their clinics and am convinced their treatments represent the gold-standard for PAD care. I was also impressed by Modern Vascular’s commitment to caring for underserved communities, especially indigenous populations in the American Southwest.”

Board Certified

Dr. Berkowitz, who is board certified in internal medicine, said he found Modern Vascular’s approach especially appealing because the procedures are minimally invasive, which means no general anesthesia and no surgery. This is particularly important given the typical age and health status of patients with peripheral artery disease. “Unfortunately, many patients are encouraged to undergo invasive vascular surgeries requiring hospitalization, and even amputations, a high-risk and life-altering surgery,” he added. “While amputations might be profitable for some practices, I believe patients and their quality-of-life matter more than profit. And I’m proud to work for a company with the mission of eliminating unnecessary amputations as the standard treatment for those with peripheral artery disease.”

New Role

In his new role, Dr. Berkowitz will ensure the best-in-class standards of care already in place at Modern Vascular clinics are enhanced, improved, and implemented as the company expands. He will also oversee the multidisciplinary panel of healthcare professionals employed by Modern Vascular, which includes Interventional Radiologists, Vascular Surgeons, and Interventional Cardiologists at the company’s 14 clinics nationwide.

“We are thrilled to welcome Dr. Berkowitz to the Modern Vascular family,” noted Dr. Yury Gampel, the company’s founder and CEO. “As the demand for our minimally invasive services continues to grow and we open more clinics across the country, it is imperative for Modern Vascular to have a full-time Chief Medical Officer who will be an advocate for innovative quality measures that improve the lives of our patients.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”